The optimal conditions for the synthesis of 11C-labelled SCH 23390 by radio-methylation of its desmethyl precursor, SCH 24518, with [11C]iodomethane are described. Isocratic reversed phase HPLC was used for the purification of [11C]SCH 23390. The specific activity range in 30 runs was 10-235 Ci/mmol
Synthesis of the labeled D1 receptor antagonist SCH 23390 using [11C]carbon dioxide
β Scribed by Siya Ram; Richard E. Ehrenkaufer; Leonard D. Spicer
- Publisher
- Elsevier Science
- Year
- 1989
- Weight
- 216 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0883-2889
No coin nor oath required. For personal study only.
β¦ Synopsis
A new synthesis is described for the production of the positron emitting radiopharmaceutical R-(+)-7-chloro-8-hydroxy-2,3,4,5-tetrahydro-3-N-[11C]methyl-1-phenyl-1H- 3-benzazepine (SCH 23390, 2a). This novel method involves reductive carboxylation, in which [11C]CO2 is reacted with the trimethylsilyl derivative of the desmethyl compound (SCH 24518, 1a) followed by treatment with lithium aluminum hydride, to afford no carrier added 11C-labeled SCH 23390. The procedure gave chemically and radiochemically pure 11C-labeled SCH 23390 in 53-72% radiochemical yield with an unoptimized specific activity of 40 Ci/mmol within 45-50 min from the end of bombardment.
π SIMILAR VOLUMES
Dopamine D 1 -receptor binding in the basal ganglia is differentially regulated by subtype nonspecific dopamine antagonists such as the antipsychotic, Fluphenazine. The purpose of the present study was to determine the relative contributions of D 1 and D 2 receptor systems in the regulation of basal
The dopamine D-1 receptor antagonist, SCH 23390 ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3- benzazepin-7-ol), was labelled by alkylation of the desmethyl compound SCH 24518 ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-5-phenyl-1H-3-benzazepin-7- ol) with [11C]methyl iodide. A multivariate o
Carbon-11 labeled SCH 23390, a selective dopamine D-1 receptor antagonist (Fig. 1b), was prepared by N-alkylation of the nor-methyl precursor with [11C]iodomethane. The product was purified by semi-preparative HPLC and shown to be radiochemically pure at the end of synthesis. The synthesis was compl
The tritium labeled form of 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e] 1,2,4-triazolo[l,5-c]pyrimidine (3H-SCH 58261) was obtained by reduction of 5-amino-7-[2-(2',4',5'-tribromo)phenylethyl]-2-(2-furyl)-pyrazolo[4,3-e] 1,2,4-triazolo[ 1,5clpyrimidine with tritium gas in the presence of 10